Outlook Therapeutics Wins FDA Appeal for $1.3B Deal | Pharma and Biotech Daily

About this episode

Outlook Therapeutics achieves a significant milestone with its FDA appeal for Lytenava in treating wet age-related macular degeneration.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of events shaping the industry, ranging from regulatory hurdles to strategic acquisitions and scientific breakthroughs. A significant milestone has been achieved by Outlook Therapeutics with its product Lytenava (bevacizumab), which recently won an appeal with the FDA for wet age-related macular degeneration treatment. This ant...

People in this episode

Host: Pharma and BioTech News

Topics covered

• FDA Appeal
• pharmaceutical developments
• biotech news
• regulatory hurdles
• strategic acquisitions
• scientific breakthroughs

Keywords

• Outlook Therapeutics
• Lytenava
• FDA
• biotech
• pharmaceutical
• regulatory
• acquisitions
• scientific breakthroughs

Mentioned in this episode

Organizations: Outlook Therapeutics

Products: Lytenava

More episodes of Pharma and BioTech Daily

• Takeda's Zasocitinib Beats Sotyktu in Phase 3 Trial | Pharma and Biotech Daily · June 12, 2026 · 5 min
• Pfizer CEO Rethinks Germany Investments Amid Reform Concerns | Pharma and Biotech Daily · June 11, 2026 · 5 min
• Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily · June 10, 2026 · 5 min
• Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily · June 9, 2026 · 5 min
• Pfizer & Chai AI Breakthrough: $1.675B Gilead Deal | Pharma and Biotech Daily · June 8, 2026 · 5 min
• Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily · June 5, 2026 · 5 min